Jansson, M.
Själander, S.
Sjögren, V.
Björck, F.
Renlund, H.
Norrving, B.
Själander, A.
Funding for this research was provided by:
Hjärt-Lungfonden (20200766)
Umea University
Article History
Accepted: 30 November 2022
First Online: 6 January 2023
Declarations
:
: Bo Norrving has received honoraria for Data Monitoring Safety Board work for Astra Zeneca (SOCRATES and THALES trials) and Bayer (NAVIGATE-ESUS trial). Anders Själander was the principal investigator of the RE-VERSE AD study in Sweden and has received consultancy and lecture fees from Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck Sharp and Dohme, Portola and Pfizer. Sara Själander has received consultancy and lecture fees from Bayer, Bristol Myers Squibb and Pfizer. The other authors have declared that no competing interests exist.